Delix Therapeutics的动态

?? Join Us for the Cell Therapy for Neurological Disorders Summit?(Dec 11th-13th , San Diego)?? I am excited to announce that I’ll be curating the audience for this upcoming summit in San Diego this December! For the first time at a cell therapy conference, the spotlight is on drug developers pioneering therapies for neurological disorders! ?? Join experts from Aspen Neuroscience, Kenai Therapeutics, Coya Therapeutics, Inteligex, and UCSD as they share their latest innovations in developing safe and effective cell therapies for the CNS, aiming to elevate the standard of care for millions affected by neurological disorders. This December, our community will dive into key topics, including: ? Preclinical and clinical findings across various indications, such as ALS, MS, Alzheimer’s, and Parkinson’s. ? The pressing need for improved preclinical models to streamline the transition to clinical trials. ? Patient challenges, including immunosuppression, placebo effects, and the delivery of these therapies to the brain and nervous system. Full session details are available here: https://ter.li/h3ogz8 Feel free to connect with me on LinkedIn or email me at [email protected] with any queries regarding this years event. Register Here : https://lnkd.in/eY9_JEnN #Celltherapy #CellTherapyNeuro #CellTherapyForNeurologicalDisorders #ALS #MS #MultipleSclerosis #Parkinsons #Alzheimers #Stroke #Epilepsy

???? This is the type of molecules that we all want to find, those with regenerative capacity, which is the new paradigm of modern medicine, to stop treating only symptoms and to be able to go to the physiopathological and biochemical basis or gene therapy, thus directing the immune system in cancer or controlling it in autoimmune diseases. In conclusion, regenerative medicine.

?? The human brain, a three-pound universe of tangled neurons and electrical impulses, holds the mysteries of our consciousness, memories, and very sense of self. Yet, this magnificent organ is tragically susceptible to a class of diseases known as neurodegenerative disorders. Alzheimer's, Parkinson's, ALS – these conditions rob individuals of their cognitive abilities, motor functions, and ultimately, their lives. #HealthTransformer #HealthMoonshot #AlzMoonshot #ENDALZ #Alzheimers #Parkinsons Read the story of how Ilios Therapeutics is pioneering a new frontier in drug discovery: multifunctional molecules for neurodegenerative conditions ?? https://ow.ly/916650SjbY8

Will you be attending the Cell Therapy for Neurological Disorders Summit this December? Boasting clinical presentations from experts including Kenai Therapeutics, Aspen Neuroscience, Inc., Neurona Therapeutics, and UC San Diego, this summit is your chance to drive innovation in neurological care. ? Find out more in our 2024 agenda: https://ter.li/vi7043 ? ?? Discuss the scope and landscape of cell therapy for neurological disease with Jim Musick and Xiaokui Zhang, PhD ?? Explore the unique challenges in manufacturing scale-up with Brian Culley ?? Evaluate preclinical models to streamline your pipeline with Mark Tuszynski, Jeanne Loring and Igor Lavrov, MD, PhD ? Intrigued? Don't miss your chance to save up to $760 on your pass - https://ter.li/ky727w #celltherapy #neurologicaldisorders #CTxNeuro

The development of PIPE-307 for treating multiple sclerosis (MS) is truly groundbreaking. Here's a fresh perspective: while this drug focuses on remyelination, could similar strategies be applied to other neurodegenerative diseases like Alzheimer's or Parkinson's? A fascinating detail: using a toxin from green mamba snake venom to pinpoint the M1R receptor exemplifies the innovative crossover between nature and technology in medical research. This kind of interdisciplinary approach might open doors to new treatments for a variety of conditions. Moreover, consider the socioeconomic impact: if PIPE-307 proves effective, it could revolutionize the cost and accessibility of MS treatment, potentially reducing long-term care costs and improving quality of life for patients globally. One question arises: how might this treatment integrate with existing MS therapies, and what are the potential implications for the standard of care? #NeuroInnovation #MedicalBreakthroughs #FutureOfHealthcare

1. Researchers introduced the "Alzheimer's in a dish" model for studying Alzheimer's disease, simulating 10-13 years of brain changes in just six weeks. 2. A new algorithm was developed to assess how well this model reflects the function and gene expression patterns of patients' brains. 3. The study confirmed that the model accurately mimics crucial pathways, aiding in rapid drug discovery. 4. Collaboration among experts in neurology and data-driven systems facilitated advancements in finding better Alzheimer's treatments. 5. The research identified 83 dysregulated pathways common to both Alzheimer's patients and the 3D cellular models. 6. A specific pathway, p38 MAPK, was tested, revealing a promising clinical inhibitor that could reduce Alzheimer’s pathology. 7. The platform allows for simultaneous testing of multiple drugs, enhancing the identification of potential therapies. 8. The advancements offer a predictive algorithm for drug efficacy, moving closer to better treatments for Alzheimer's disease.

BioArctic AB's partner, Eisai, has achieved a significant milestone with the approval of Leqembi? (lecanemab) for Alzheimer's treatment in Israel. Leqembi, an anti-amyloid beta protofibril antibody, targets and reduces amyloid-beta buildup in the brain, a key factor in Alzheimer's pathology. This approval is a major advancement in global efforts to develop effective therapies and offers new hope to millions affected by this neurodegenerative disorder. Read the full article at https://lnkd.in/eTZMAkYB

The Parkinson's Solutions Summit 2.0 has featured truly exceptional speakers so far. There's still time to register for my presentation today, where I'll discuss our Research Use Only test that detects all stages and subcategories of Parkinson's disease—even in asymptomatic individuals who have been exposed to COVID-19. Hope to see you at the Summit! #dementia #alzheimers #venturecapital #angelinvestor #cancer #hivaids??#bioOS?#biotechnology?#diagnostics #innovation?#technology?#management?#startups?#liquidbiopsy #neurodegenerativediseases?#multiplesclerosis?#parkinsonsdisease?#alzheimersdisease?#longhaulers?#longcovid?#humangenome?#onetestonelife #longevity?#artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine #ClinicalResearch #COVID19 #Parkinsons #climatechange

??Proud to Share My Latest Publication! ?? I am excited to announce the publication of my article titled “A Rare Case of Juvenile Granulosa Cell Tumor in a Premenarchal Female: Clinical Presentation, Diagnosis, and Management”. This case report highlights the unique clinical presentation, diagnostic challenges, and management strategies for a rare ovarian tumor in a young patient. Juvenile granulosa cell tumors are uncommon, and documenting such cases contributes significantly to advancing understanding and treatment in pediatric gynecology and oncology. I extend my heartfelt thanks to my mentors, collaborators, and supporters who played an instrumental role in this work. You can read the full article here #Research #Publication #Pediatrics #Oncology #CaseReport

Click here:https://lnkd.in/d4UP8pcb ?? The #GlobalNeurofibromatosisTreatment Market is set to reach US$ 27.06 Bn by the end of the forecast period, growing at a robust CAGR of 13.3%. ?? Neurofibromatosis is a genetic disorder leading to tumor formation on nerve tissues, affecting the #Brain, #SpinalCord, and #Nerves. It includes three types: #NF1, #NF2, and #Schwannomatosis. While NF1 is typically diagnosed in childhood, NF2 and Schwannomatosis often appear in early adulthood. ?? Ongoing #R&D efforts and advancements in novel therapies are key drivers of market growth. Increased awareness, better diagnosis methods, and rising #HealthcareExpenditure are contributing to the expanding demand for effective treatments. ?? The Children’s Tumor Foundation (CTF) is a major supporter of #Neurofibromatosis research, pushing for better therapies through initiatives like the Neurofibromatosis Preclinical Consortium (NFPC). ?? APAC is emerging as a future hotspot for market growth, with a focus on advanced technologies and new product launches. #GeneticDisorders #NeurofibromatosisAwareness #HealthcareInnovation #MedicalResearch #TumorTreatment #GlobalHealth #APACGrowth #PharmaceuticalIndustry